| Index | — | P/E | 137.61 | EPS (ttm) | 1.18 | Insider Own | 18.75% | Shs Outstand | 25.01M | Perf Week | -2.16% |
| Market Cap | 4.06B | Forward P/E | 16.80 | EPS next Y | 9.67 | Insider Trans | -0.95% | Shs Float | 24.56M | Perf Month | 1.88% |
| Enterprise Value | 5.03B | PEG | 22.45 | EPS next Q | 2.14 | Short Float | 6.98% | Perf Quarter | -5.57% | ||
| Income | 30.00M | P/S | 1.88 | EPS this Y | 15.43% | Short Ratio | 6.25 | Perf Half Y | 36.83% | ||
| Sales | 2.16B | P/B | 1.89 | EPS next Y | 10.61% | ROA | 0.76% | Short Interest | 1.71M | Perf YTD | 13.82% |
| Book/sh | 86.06 | P/C | 13.63 | EPS next 5Y | 6.13% | ROE | 1.41% | 52W High | 192.85 -15.80% | Perf Year | 35.61% |
| Cash/sh | 11.92 | P/FCF | 26.37 | EPS past 3/5Y | — -62.60% | ROIC | -21.74% | 52W Low | 113.37 43.23% | Perf 3Y | 60.66% |
| Dividend Est. | — | EV/EBITDA | 20.30 | Sales past 3/5Y | -0.74% 11.90% | Gross Margin | 37.56% | Volatility | 3.47% 2.98% | Perf 5Y | -27.80% |
| Dividend TTM | — | EV/Sales | 2.33 | EPS Y/Y TTM | — | Oper. Margin | 5.04% | ATR (14) | 5.12 | Perf 10Y | 14.02% |
| Dividend Ex-Date | — | Quick Ratio | 1.21 | Sales Y/Y TTM | -9.02% | Profit Margin | 1.39% | RSI (14) | 48.04 | Recom | 2.00 |
| Dividend Gr. 3/5Y | — | Current Ratio | 2.43 | EPS Q/Q | 12.86% | SMA20 | -0.43% | Beta | 0.87 | Target Price | 192.25 |
| Payout | 0.00% | Debt/Eq | 0.59 | Sales Q/Q | 0.55% | SMA50 | -0.87% | Rel Volume | 1.22 | Prev Close | 163.78 |
| Employees | 13,000 | LT Debt/Eq | 0.58 | Earnings | Nov 05 | SMA200 | 9.25% | Avg Volume | 254.69K | Price | 162.38 |
| IPO Date | Mar 31, 1992 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 23.85% 2.71% | Net Debt/EBITDA | 3.92 | Volume | 309,977 | Change | -0.85% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Aug-07-26 | Reiterated | Raymond James | Strong Buy | $97 → $200 |
| Aug-07-26 | Reiterated | Needham | Buy | $165 → $187 |
| Aug-07-26 | Reiterated | BTIG | Buy | $170 → $200 |
| Jul-21-26 | Reiterated | Keybanc | Overweight | $164 → $182 |
| Jun-15-26 | Initiated | BTIG | Buy | $170 |
| May-27-26 | Upgrade | Needham | Hold → Buy | $165 |
| Apr-27-26 | Reiterated | Keybanc | Overweight | $180 → $164 |
| Apr-17-26 | Reiterated | Piper Sandler | Overweight | $178 → $163 |
| Feb-20-26 | Reiterated | Keybanc | Overweight | $173 → $180 |
| Feb-20-26 | Reiterated | Piper Sandler | Overweight | $153 → $178 |
ICU Medical, Inc., operating globally through its subsidiaries, is a medical technology firm that specializes in the development, manufacture, and sale of devices for both infusion therapy and critical care. Their extensive product line for infusion therapy encompasses: Needlefree Connectors: Such as the MicroClave, MicroClave Clear, and NanoClave brands. Catheter Maintenance & Disinfection: Including Neutron patency devices and SwabCap/SwabTip disinfecting caps. Hemodialysis Solutions: Like Tego connectors and ClearGuard HD antimicrobial caps. Hazardous Drug Handling: With closed system transfer devices (ChemoClave, ChemoLock) and the Diana compounding system for safe preparation. They also provide a comprehensive range of intravenous (IV) solutions, diluents, and irrigation fluids, available in diverse packaging options like flexible containers and pour bottles. These include common formulations such as sodium chloride, dextrose, balanced electrolytes, lactated ringer's, mannitol, and sterile water, alongside specialized irrigation solutions like acetic acid and glycine. In medication management, ICU Medical offers sophisticated infusion pumps, including the Plum 360 and LifeCare PCA brands. Its advanced ICU Medical MedNet software enhances medication safety by integrating smart pumps with hospital electronic health records (EHRs), asset tracking, and alarm notification platforms. Accompanying professional services are also provided. For critical care environments, their portfolio features: Hemodynamic Monitoring: Systems like Cogent 2-in-1 and CardioFlo. Cardiac Output & Oximetry: TDQ, OptiQ, and TriOx catheters. Blood Pressure Transducers: Such as Transpac. Blood Sampling Systems: Including the SafeSet closed blood sampling and conservation systems. The company distributes its products to a wide spectrum of healthcare providers, including acute care hospitals, wholesalers, ambulatory clinics, and various alternate site facilities such as outpatient clinics, home healthcare services, and long-term care centers. Established in 1984, ICU Medical maintains its headquarters in San Clemente, California.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 2,159 | 2,230 | 2,382 | 2,259 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 1,348 | 1,410 | 1,557 | 1,519 | — | — | — | — | — | |
| Gross Profit | 811 | 820 | 825 | 740 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 616 | 625 | 639 | 607 | — | — | — | — | — | |
| Research and Development | 86 | 87 | 89 | 85 | — | — | — | — | — | |
| Other Operating Expense | 0 | 1 | 54 | 25 | — | — | — | — | — | |
| Operating Income | 109 | 107 | 43 | 23 | — | — | — | — | — | |
| Interest Expense | 84 | 105 | 107 | 103 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -30 | 2 | -2 | 2 | — | — | — | — | — | |
| Net Income Before Taxes | -4 | 3 | -66 | -78 | — | — | — | — | — | |
| Income Taxes | -32 | 2 | 52 | -49 | — | — | — | — | — | |
| Consolidated Net Income | 30 | 1 | -118 | -30 | — | — | — | — | — | |
| Net Income From Continuing Operations | 27 | 1 | -118 | -30 | — | — | — | — | — | |
| Net Income | 30 | 1 | -118 | -30 | — | — | — | — | — | |
| EPS (Recurring) | 1.20 | 0.03 | -4.83 | -1.23 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 1.20 | 0.03 | -4.83 | -1.23 | — | — | — | — | — | |
| EPS (Diluted) | 1.18 | 0.03 | -4.83 | -1.23 | — | — | — | — | — | |
| EBITDA | 248 | 309 | 260 | 253 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 137.61 | 4,852.72 | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 1.88 | 1.60 | 1.56 | 1.06 | — | — | — | — | — | |
| Gross Margin | 37.56 | 36.77 | 34.63 | 32.76 | — | — | — | — | — | |
| Operating Margin | 5.05 | 4.80 | 1.81 | 1.02 | — | — | — | — | — | |
| Net Margin | 1.39 | 0.04 | -4.95 | -1.33 | — | — | — | — | — | |
| Shares Outstanding | 25 | 25 | 24 | 24 | — | — | — | — | — | |
| Market Capitalization | 4,060 | 3,567 | 3,724 | 2,394 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Sanzone Virginia Ruth | VP, General Counsel | Sep 03 '26 | Sale | 168.69 | 4,856 | 819,150 | 14,604 | Sep 03 |
| Bonnell Brian Michael | Chief Financial Officer | Sep 01 '26 | Sale | 175.00 | 6,381 | 1,116,675 | 56,062 | Sep 01 |
| Bonnell Brian Michael | Chief Financial Officer | Aug 31 '26 | Sale | 172.79 | 9,307 | 1,608,144 | 62,443 | Aug 31 |
| Woolson Daniel | VP, GM-Infusion Capital | Aug 13 '26 | Sale | 181.33 | 5,417 | 982,265 | 17,062 | Aug 13 |
| Sousa Ben | Chief Information Officer | Aug 12 '26 | Sale | 178.32 | 2,250 | 401,209 | 3,076 | Aug 12 |
| Voigtlander Christian B. | Chief Operating Officer | Aug 11 '26 | Sale | 182.93 | 8,929 | 1,633,404 | 37,377 | Aug 11 |
| FINNEY ELISHA W | Director | Aug 11 '26 | Sale | 182.48 | 378 | 68,978 | 4,871 | Aug 11 |
| Woolson Daniel | President | May 22 '26 | Sale | 132.21 | 2,123 | 280,685 | 22,479 | May 22 |
| Sanzone Virginia Ruth | VP, General Counsel | May 14 '26 | Sale | 124.08 | 2,447 | 303,624 | 19,460 | May 15 |
| KENNEDY KOLLEEN T | Director | May 13 '26 | Option Exercise | 0.00 | 1,254 | 0 | 4,539 | May 13 |
| Hernandez Laurie | Director | May 13 '26 | Option Exercise | 0.00 | 1,254 | 0 | 4,862 | May 13 |
| FINNEY ELISHA W | Director | May 13 '26 | Option Exercise | 0.00 | 1,254 | 0 | 5,249 | May 13 |
| Abbey Donald | Director | May 13 '26 | Option Exercise | 0.00 | 1,254 | 0 | 6,004 | May 13 |
| Hoffmeister David F | Director | May 13 '26 | Option Exercise | 0.00 | 1,254 | 0 | 6,004 | May 13 |
| Greenberg David C. | Director | May 13 '26 | Option Exercise | 0.00 | 1,254 | 0 | 9,214 | May 13 |